-
UK agrees support for Saudi in struggle with Houthis: reports
-
Green policies just good politics, says UK minister
-
EU foreign policy chief calls for continued sanctions on Russia
-
Bardot auction in Paris fetches nearly one million euros
-
Flights scrapped, evacuations urged as Typhoon Dujuan wallops Japan
-
No timeline on Daniels injury return, says Commanders coach
-
Fonseca to take break from tennis
-
British Columbia sues OpenAI in US court over Canada school shooting
-
A Cuban zoo, and its animals, in epic battle for survival
-
French star Batum retires after 18-year NBA career
-
Infantino proposes consulting federations to reform FIFA
-
Zidane leads first France training session
-
El Nino weather pattern enters record territory: scientist
-
Man shot by ICE agent in Texas detained with bullet inside him: lawyer
-
OpenAI calls for US to lead global effort on AI standards
-
California declares state of emergency ahead of El Nino
-
South African ostriches plucked alive for luxury fashion: report
-
South Africa arrests three more suspects, after nine women murdered
-
US networks halt Trump coverage in revolt over White House ban
-
Carse needs time away from England, says captain Brook
-
Paramount settles with US states to clear Warner Bros. mega-merger
-
NOWPayments Releases Cross-Chain Payout Data Revealing Key Performance Benchmarks Across TRON, BNB Chain, and Solana
-
Climate crisis a job for world leaders, not just activists: UK FM
-
British Museum bans photos of Bayeux Tapestry as crowds linger
-
US networks halt Trump coverage over White House ban
-
COP31 host says AI climate footprint to be a summit priority
-
French singer accuses Miley Cyrus of plagiarism
-
Berlin's far-left vote winners reject anti-semitism charges
-
EU fines Google 403 mn euros for location data breach
-
Mancini eager for 'new adventure' on Italy return
-
'Best is yet to come,' says De la Fuente after Spain extension
-
Mbappe says having Zidane as France coach 'like a film'
-
Why diesel prices are rising more than crude oil
-
Palmer, Rice out of England Nations League squad
-
COP31 host says AI's climate footprint to be a summit priority
-
German auto workers stage mass protests in bid to save jobs
-
Renewables hit record in 2025, but world must move faster: report
-
Embattled Merz vows to keep ruling for 'democratic future' of Germany
-
US media outlets to sue Trump administration after White House ban
-
Merz vows to keep ruling coalition together for 'democratic future' of Germany
-
Global stocks rally on lower oil prices, US-China hopes
-
Spain coach De la Fuente gets new deal after World Cup success
-
EU proposes energy rating for data centres
-
Pressure grows on Germany's Merz after election defeats
-
Schoolgirl Yu scorches to second gold as doping case rocks Games
-
China's Zhang beats Japan rivals to Asian Games gymnastics gold
-
Putin's party secures record score in Russia election
-
Samlingen Haupt: Vad pengar avslöjar om oss människor
-
Haupt Koleksiyonu: Paranın Biz İnsanlar Hakkında Anlattıkları
-
Tens of thousands of German auto workers protest to save jobs
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Schubert--BTB